Vaporized THC/CBD Shows Significant Symptom Relief for MS Patients
Around 20–30% of MS patients report using cannabis to manage symptoms like tremors, pain, or sleep problems.
In a March 2025 study, researchers evaluated a vaporized formulation of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) in people with Multiple Sclerosis. The results, collected over a six-month period, showed improvements in muscle spasticity and urinary bladder dysfunction, with a slight reduction in overall disability progression. This adds to existing evidence that cannabis-based therapies can help relieve certain MS symptoms.
The Growing Role of Cannabinoids in Multiple Sclerosis (MS) Management
If you or a loved one lives with Multiple Sclerosis (MS), you know the daily battle. MS is a complex, chronic illness that attacks the central nervous system, and its symptoms—from agonizing muscle stiffness (spasticity) to constant fatigue and bladder issues—can be relentless.
For years, cannabis has been a go-to for MS patients seeking relief beyond conventional drugs. Sativex, a THC/CBD spray approved in other countries for spasticity, exists—but scientific support has lagged behind patient reports.
A significant new piece of research, published in the Journal of Clinical Medicine in March 2025, has provided some of the clearest clinical evidence yet. This prospective study tracked MS patients who used vaporized cannabis, and the results were nothing short of remarkable, reporting “significant improvements… across all outcome assessments.”
“The findings of this study highlight the potential benefits of CBD13/THC9 vaporized formulations in managing MS symptoms,” the study authors wrote, “particularly when integrated into the existing treatment framework of DMTs and other MS symptomatic therapies.”
Let’s break down exactly what the researchers found and why this study could be a game-changer for medical cannabis patients and their doctors.
How 69 MS Patients Were Tracked for 6 Months: The Study Design.
What makes this study stand out is its practical, real-world design. Titled, “Evaluating Vaporized Cannabinoid Therapy in Multiple Sclerosis: Findings from a Prospective Single-Center Clinical Study”, it was conducted by a research team in Greece, and it accommodated almost 70 participants.
Here are the key details:
- The Participants: The study included 69 individuals with Multiple Sclerosis who were experiencing symptoms like muscle spasticity, disease progression, and bladder dysfunction.
- The Medicine: Participants were instructed to use a vaporized cannabis flower with a very specific, high-CBD-dominant ratio: 13% CBD and 9% THC. This is a crucial detail, as the exact ratio of cannabinoids often determines the therapeutic effect.
- The Timeline: The researchers measured the participants’ symptoms at baseline, then again after three months, and finally at six months, providing a clear picture of sustained relief over time.
By tracking specific, measurable outcomes over a half-year period, this study gives us high-level medical data on how a particular cannabis product works in a specific patient population.
The Spasticity Scorecard: Major Gains for Mobility and Function.
The most debilitating symptom for many MS patients is spasticity, the involuntary, often painful stiffness and cramping of the muscles. The March 2025 study focused heavily on this, and the results were overwhelmingly positive.
The researchers observed significant and consistent improvement in spasticity and the overall rate of disability progression in the participants.
Relief from spasticity doesn’t just mean a reduction in pain; it means improved mobility, better sleep, and less reliance on other anti-spasticity medications that often come with harsh side effects. The data suggests that for a large majority of the participants, this THC/CBD combination offered a superior and well-tolerated treatment option.
More Than Just Muscles: Improving Bladder Control and Daily Life.
While spasticity gets the most attention, the study also tracked other vital, quality-of-life symptoms—and delivered more good news.
Cannabinoid therapy led to significant improvements in bladder dysfunction. Bladder problems are a common, frustrating, and often embarrassing part of living with MS. Finding a natural therapy that can help regulate these functions is a major win for patient autonomy and daily comfort.
Furthermore, cannabinoids are renowned for their ability to treat neuropathic pain, the nerve-related burning and tingling sensations common in MS. Although the primary focus was on spasticity, the overall positive results across “all outcome assessments” strongly suggest that the cannabis blend’s comprehensive anti-inflammatory and pain-relieving effects were at play.
The Cannabinoid Ratio: Why 9% THC and 13% CBD Was Effective?
The specific chemistry of the vaporized cannabis—the 9% THC and 13% CBD ratio—is arguably the most important element of the study. This ratio highlights a key concept in cannabis science: The Entourage Effect.
Instead of focusing on THC or CBD alone, the Entourage Effect suggests that all the compounds in the plant—cannabinoids, terpenes, and flavonoids—work better together than in isolation.
In this blend, the two primary cannabinoids likely played complementary roles:
- THC (9%): Responsible for the primary analgesic (pain-killing) and anti-spastic effects by activating CB1 receptors in the central nervous system.
- CBD (13%): Likely provided anti-inflammatory action, reduced the potential psychoactivity of the THC, and contributed to anxiety relief and better sleep—all of which indirectly improve MS symptoms.
The 13% CBD content ensures that patients get maximum therapeutic benefit while keeping the THC level moderate, which minimizes side effects like transient anxiety or sedation.
Mechanism of Action: How Cannabinoids Target MS?
How does cannabis actually help a disease as complicated as MS? It comes down to your body’s own master regulator: the Endocannabinoid System (ECS).
The ECS is a vast network of receptors (CB1 and CB2) and natural cannabis-like molecules (endocannabinoids) that manage functions like pain, inflammation, mood, and immune response.
MS is an autoimmune disorder—it involves the immune system mistakenly attacking the body’s nerve coverings. Cannabinoids like THC and CBD work by interacting directly with the ECS:
- Anti-Inflammatory Action: Cannabinoids, especially CBD and through CB2 receptor activation, are powerful anti-inflammatories. They help to cool down the chronic inflammation that damages nerves in MS.
- Nerve Protection: By calming overactive nerve signaling (via CB1 receptors), THC helps to reduce muscle stiffness and spasticity.
In short, cannabis is helping the body restore balance and quiet the hyper-alert immune response that characterizes MS.
Moving the Needle: Why More Large-Scale Research Is Crucial.
This 2025 study offers substantial, patient-driven data, but it is not the final word. The reported ‘significant improvements’ give the medical community the evidence it needs to take the next steps.
The immediate takeaway for patients and clinicians is that a balanced, CBD-dominant, vaporized cannabis approach appears to be highly effective and well-tolerated.
The next steps for the scientific community will be to conduct even larger, multinational, double-blind, placebo-controlled trials to definitively confirm these positive outcomes.
For now, this new research suggests that plant-based therapies may offer a helpful option for managing some of the challenging symptoms of Multiple Sclerosis, though results should be viewed as promising rather than definitive.
Read more from Soft Secrets:
S
Stephen Andrews
